Home
About
Overview
Sharing Data
ORCID
Help
History (54)
Afatinib for lung cancer: let there be light?
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
See All 54 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015 Oct; 26(10):2079-84.
View in:
PubMed
subject areas
Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
ErbB Receptors
Erlotinib Hydrochloride
Follow-Up Studies
Humans
Lung Neoplasms
Mutation
Neoplasm Staging
Prognosis
Prospective Studies
Proto-Oncogene Proteins p21(ras)
Survival Rate
Taxoids
authors with profiles
Marina Chiara Garassino